HPV Vaccines: Preclinical Development

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 466-470

  Gissmann, Lutz ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM SALT; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; STRUCTURAL PROTEIN; WART VIRUS VACCINE;

BASEMENT MEMBRANE; CLINICAL TRIAL; EPITHELIUM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNITY; KERATINOCYTE; NONHUMAN; REVIEW; UTERINE CERVIX CANCER; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS PARTICLE; WART VIRUS;

ANIMALS; FEMALE; FORECASTING; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 70350075480     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.07.002     Document Type: Review

References (53)

1. Galloway D.A. Serological assays for the detection of HPV antibodies. In: Munoz N., Bosch F.X., Shah K.V., and Meheus A. (Eds). The Epidemiology of Human Papillomavirus and Cervical Cancer (1992), IARC Scientific Publications, Lyon 147-161
2. Jochmus-Kudielka I., Schneider A., Braun R., et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 81 (1989) 1698-1704
3. Meschede W., Zumbach K., Brasspenning J., et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 36 (1998) 475-480
4. Hagensee M.E., Koutsky L.A., Lee S.K., et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis 181 (2000) 1234-1239
5. Onda T., Carter J.J., Koutsky L.A., et al. Characterization of IgA response among women with incident HPV 16 infection. Virology 312 (2003) 213-221
6. Ho G.Y., Studentsov Y., Hall C.B., et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186 (2002) 737-742
7. Viscidi R.P., Ahdieh-Grant L., Clayman B., et al. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 187 (2003) 194-205
8. Pastrana D.V., Gambhira R., Buck C.B., et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 (2005) 365-372
9. Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
10. Kirnbauer R., Chandrachud L.M., O'Neil B.W., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 (1996) 37-44
11. Suzich J.A., Ghim S.J., Palmer-Hill F.J., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 (1995) 11553-11557
12. Pilacinski W.P., Glassman D.L., Glassman K.F., et al. Immunization against bovine papillomavirus infection. Ciba Found Symp 120 (1986) 136-156
13. Ghim S., Newsome J., Bell J., et al. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 68 (2000) 147-151
14. Thones N., Herreiner A., Schadlich L., et al. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 82 (2008) 5472-5485
15. Stahl-Hennig C., Eisenblatter M., Jasny E., et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5 (2009) e1000373
16. Makowski L. Structural studies of the assembly of simple viruses. Prog Clin Biol Res 40 (1980) 233-258
17. Salunke D.M., Caspar D.L., and Garcea R.L. Self-assembly of purified polyomavirus capsid protein VP1. Cell 46 (1986) 895-904
18. Kirnbauer R., Taub J., Greenstone H., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67 (1993) 6929-6936
19. Combita A.L., Bravo M.M., Touzé A., Orozco O., and Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 97 (2002) 796-803
20. Pastrana D.V., Buck C.B., Pang Y.Y., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 (2004) 205-216
21. Brown D.R., Fife K.H., Wheeler C.M., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 (2004) 2936-2942
22. Harro C.D., Pang Y.Y., Roden R.B., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-292
23. Carter J.J., Koutsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 (2000) 1911-1919
24. Fausch S.C., Da Silva D.M., and Kast W.M. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 63 (2003) 3478-3482
25. Koromilas A.E., Li S., and Matlashewski G. Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 12 (2001) 157-170
26. Nardelli-Haefliger D., Wirthner D., Schiller J.T., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 (2003) 1128-1137
27. Balmelli C., Roden R., Potts A., et al. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72 (1998) 8220-8229
28. Ruiz W., McClements W.L., Jansen K.U., et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 3 (2005) 2
29. De Gregorio E., Tritto E., and Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38 (2008) 2068-2071
30. Baldridge J.R., McGowan P., Evans J.T., et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4 (2004) 1129-1138
31. Ismaili J., Rennesson J., Aksoy E., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 (2002) 926-932
32. Rambout L., Hopkins L., Hutton B., et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177 (2007) 469-479
33. Opalka D., Lachman C.E., MacMullen S.A., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10 (2003) 108-115
34. Einstein MH. On behalf of the HPV-010 Study group. Immune response after primary vaccination course: a comparative trial of two prophylactic vaccines. In: Dillner J, ed. 25th International Papillomavirus Conference. Malmö/Sweden; 2009.
35. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
36. Villa L.L., Ault K.A., Giuliano A.R., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
37. Giuliano A.R., Lazcano-Ponce E., Villa L., et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196 (2007) 1153-1162
38. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
39. Olsson S.E., Villa L.L., Costa R.L., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
40. Lehtinen M., Apter D., Dubin G., et al. Enrollment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 17 (2006) 517-521
41. Wheeler C.M., Kjaer S.K., Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199 (2009) 936-944
42. Alphs H.H., Gambhira R., Karanam B., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105 (2008) 5850-5855
43. Pastrana D.V., Gambhira R., Buck C.B., et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 (2005) 365-372
44. DeFilippis R.A., Goodwin E.C., Wu L., et al. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 77 (2003) 1551-1563
45. Butz K., Ristriani T., Hengstermann A., et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22 (2003) 5938-5945
46. Chen X.S., Garcea R.L., Goldberg I., et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5 (2000) 557-567
47. Schädlich L., Senger T., Gerlach B., et al. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 83 15 (2009 Aug) 7690-705. Epub 2009 May 20
48. Biemelt S., Sonnewald U., Galmbacher P., et al. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 77 (2003) 9211-9220
49. Maclean J., Koekemoer M., Olivier A.J., et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 88 (2007) 1460-1469
50. Nardelli-Haefliger D., Lurati F., Wirthner D., et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 (2005) 3634-3641
51. Schiller J.T., and Nardelli-Haefliger D. Chapter 17: Second generation HPV vaccines to prevent cervical cancer. Vaccine 24 suppl 3 (2006) S147-S153
52. Kuck D., Lau T., Leuchs B., et al. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 80 (2006) 2621-2630
53. Revaz V., Zurbriggen R., Moser C., et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 76 (2007) 75-85